A recent retrospective study published in the Indian Journal of Gynecologic Oncology in October 2026 reveals survival disparities in clear cell carcinoma across anatomical sites, emphasizing the need for tailored multimodality care. Five-year overall survival rates reached 71.7% for ovarian and 61.2% for endometrial cases but dropped sharply to 44.4% in cervical malignancies.

Gynecologic clear cell carcinoma is a rare, aggressive malignancy with heterogeneous anatomical behavior, yet limited evidence exists regarding site-specific prognostic drivers in low- and middle-income country healthcare settings. Addressing this critical clinical gap, G. Y. Srinivasa and co-investigators from a tertiary care cancer center in India performed a retrospective cohort study to systematically evaluate the clinicopathologic features, treatment regimens, survival trajectories, and prognostic factors of clear cell carcinoma arising in the endometrium, ovary, and cervix.

Therefore, the 10-year retrospective study evaluated 81 patients with gynecologic clear cell carcinoma across ovarian (40), endometrial (27), and cervical (14) sites to compare site-specific surgical and chemoradiation regimens. Using Kaplan–Meier survival modeling and Cox regression analysis, researchers assessed 5-year overall survival and key prognostic drivers across all three cohorts.

Key clinical findings of the study includes:

  • Age Variations at Diagnosis: This report established that endometrial clear cell carcinoma affects older individuals with a median age of 65.0 years, whereas cervical and ovarian presentations occur in younger cohorts at median ages of 52.5 and 48.5 years, respectively.
  • Disparate Stage Distribution: The investigation revealed that early-stage disease dominated in ovarian (72.5%) and endometrial (55.5%) subtypes, while cervical carcinomas presented predominantly at stage II (64.3%).
  • Site-Specific Survival Divergence: The analysis demonstrated distinct 5-year overall survival rates across anatomical sites, recorded at 71.7% for ovarian, 61.2% for endometrial, and 44.4% for cervical malignancies.
  • Independent Prognostic Drivers: The study identified advanced International Federation of Gynecology and Obstetrics (FIGO) stage, lymphovascular space invasion (LVSI), and regional lymph node involvement as significant determinants of diminished patient survival.

The results suggest that clear cell carcinoma of the female genital tract displays marked site-specific clinical profiles and survival variances—ranging from a 71.7% 5-year overall survival rate in ovarian disease to 44.4% in cervical cases—demanding aggressive, tailored multimodality treatment strategies.

Thus, the study concludes that clinicians may consider adopting rigorous surgical staging, early diagnostic protocols, and risk-adapted multidisciplinary management strategies to optimize long-term outcomes in patients diagnosed with these rare gynecologic tumors.

While the single-center retrospective design and sample size variations across subgroups represent inherent study constraints, future collaborative multicenter registries could further validate these findings and strengthen the evidence base for managing uncommon gynecologic malignancies.

Reference

Srinivasa GY, Dey T, Gupta N, Rai B, Saha SC, Bagga R, Jain V, Srinivasan R, Ghoshal S. Clinicopathologic Spectrum and Treatment Outcomes of Clear Cell Carcinoma of the Female Genital Tract: A Decade of Experience from a Tertiary Care Centre. Indian Journal of Gynecologic Oncology. 2026;24:111.



Tags:    
Article Source : Indian Journal of Gynecologic Oncology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .